Sheila Frame: What Excites Sandoz About Biosimilars

Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, explains what about biosimilars excites the company. 
June 20, 2018
 

Transcript

So at Sandoz we're just so thrilled with the experience. We have 20 years' worth of experience in biologics, 340 million patient days of exposures to biosimilars in 86 countries. We are so excited for the value that we can bring to Americans. They so deserve getting access to these important products, both from us and from our industry colleagues, in order to free up capacity for the new innovations that are coming, but also, and importantly, to get the benefit of the savings and increased access that they'll have.

 

x-button

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.